From delocalized lipophilic cations to hypoxia: Blocking tumor cell mitochondrial function leads to therapeutic gain with glycolytic inhibitors

Molecular Nutrition and Food Research

Volumn 53, Issue 1, 2009, Pages 68-75

  Kurtoglu, Metin ^a   Lampidis, Theodore J ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Anthracycline; Cancer; Delocalized lipohilic cation; Hypoxia; Mitochondria

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CATION; DEOXYGLUCOSE; RHODAMINE 123;

ANOXIA; CELL HYPOXIA; CHEMISTRY; DRUG EFFECT; GLYCOLYSIS; HUMAN; METABOLISM; MITOCHONDRION; NEOPLASM; PATHOLOGY; PATHOPHYSIOLOGY; REFERENCE VALUE; REVIEW;

ANOXIA; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; CATIONS; CELL HYPOXIA; DEOXYGLUCOSE; GLYCOLYSIS; HUMANS; MITOCHONDRIA; NEOPLASMS; REFERENCE VALUES; RHODAMINE 123;

EID: 58149343972     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.200700457     Document Type: Review

References (77)

1. Bonadonna, G., Monfardini, S., Cardiac toxicity of daunorubicin, Lancet 1969, 1, 837.
2. Cortes, E. P., Gupta, M., Chou, C., Amin, V. C., Folkers, K., Adriamycin cardiotoxicity: Early detection by systolic time interval and possible prevention by coenzyme Q1, Cancer Treat Rep. 1978, 62, 887-891.
3. Lampidis, T. J., Henderson, I. C., Israel, M., Canellos, G. P., Structural and functional effects of adriamycin on cardiac cells in vitro, Cancer Res. 1980, 40, 3901-3909.
4. Lampidis, T. J., Johnson, L. V., Israel, M., Effects of adriamycin on rat heart cells in culture: Increased accumulation and nucleoli fragmentation in cardiac muscle v. nonmuscle cells, J. Mol. Cell. Cardiol. 1981, 10, 913-924.
5. Lampidis, T. J., An in vitro model of anthracycline cardiopathogenesis, Mathe, G., Maral, R., De Jager, M. (Eds.), in: Anthracyclines 1981: Current Status and Future Development, Masson Publication, New York 1983, Chapter 6.
6. Summerhayes, I. C., Lampidis, T. J., Bernal, S. D., Nadakavukaren, J. J. et al., Unusual retention of rhodamine 123 by mitochondria in muscle and carcinoma cells, Proc. Natl. Acad. Sci. USA 1982, 79, 5292-5296.
7. Lampidis, T. J., Savaraj, N., Valet, G. K., Trevorrow, K. et al., Relationship of chemical charge of anticancer agents to increased accumulation and cytotoxicity in cardiac and tumor cells: Relevance to multidrug resistance, J. Cell Pharm. 1989, 89, 16-22.
8. Lampidis, T. J., Salet, C., Moreno, G., Chen, L. B., Effects of the mitochondrial probe rhodamine 123 and related analogs on the function and viability of pulsating myocardial cells in culture, Agents Actions 1984, 14, 751-757.
9. Johnson, L. V., Walsh, M. L., Bockus, B. J., Chen, L. B., Monitoring of relative mitochondrial membrane potential in living cells by fluorescence microscopy, J. Cell. Biol. 1981, 88, 526-535.
10. Chen, L. B., Summerhayes, I. C., Johnson, L. V., Walsh, M. L. et al., Probing mitochondria in living cells with rhodamine 123, Cold Spring Harb. Symp. Quant. Biol. 1982, 46, 141-155.
11. Johnson, L. V., Walsh, M. L., Chen, L. B., Localization of mitochondria in living cells with rhodamine 123, Proc. Natl. Acad. Sci. USA 1980, 77, 990-994.
12. El Baraka, M., Deumie, M., Viallet, P., Lampidis, T. J., Fluorescence properties and partitioning behaviour of esterified and unesterified rhodamines, J. Photochem. Photobiol. A: Chem. 1991, 17, 234-251.
13. Chen, L. B., Mitochondrial membrane potential in living cells, Ann. Rev. Cell. Biol. 1988, 4, 155-181.
14. Johnson, L. V., Summerhayes, I. C., Chen, L. B., Decreased uptake and retention of rhodamine 123 by mitochondria in feline sarcoma virus-transformed mink cells, Cell 1982, 28, 7-14.
15. Reed, P. W., Ionophores, Meth. Enzymol. 1979, 31, 435.
16. Lampidis, T. J., Bernal, S. D., Summerhayes, I. C., Chen, L. B., Rhodamine-123 is selectively toxic and preferentially retained in carcinoma cells in vitro, Ann. NY Acad. Sci. 1981, 14, 299-303.
17. Lampidis, T. J., Bernal, S. D., Summerhayes, I. C., Chen, L. B., Selective toxicity of rhodamine 123 in carcinoma cells in vitro, Cancer Res. 1983, 43, 716-720.
18. Lampidis, T. J., Hasin, Y., Weiss, M. J., Chen, L. B., Selective killing of carcinoma cells in vitro by lipohilic-cationic compounds: Cellular basis, Biomed. Pharmacother. 1985, 39, 220-226.
19. Bernal, S. D., Lampidis, T. J., McIsaac, R. M., Chen, L. B., Anticarcinoma activity in vivo of rhodamine 123, a mitochondrial-specific dye, Science 1983, 222, 169-172.
20. Modica-Napolitano, J. S., Weiss, M. J., Chen, L. B., Aprille, J. R., Rhodamine 123 inhibits bioenergetic function in isolated rat liver mitochondria, Biochem. Biophys. Res. Commun. 1984, 118, 717-723.
21. Lampidis, T. J., Savaraj, N., Valet, G. K., Trevorrow, K. et al., Relationship of chemical charge of anti-cancer agents to increased accumulation and cytotoxicity in cardiac and tumor cells: Relevance to multi-drug resistance, Tapiero, H., Robert, J., Lampidis, T. J. (Eds.), in: Anticancer Drugs, Collosque Inserm, John Libbey, Eurotext Ltd., London 1989, pp. 29-38.
22. Davis, S., Weiss, M. J., Wong, J. R., Lampidis, T. J., Chen, L. B., Mitochondrial and plasma membrane potentials cause unusual accumulation and retention of rhodamine 123 by human breast adenocarcinoma-derived MCF-7 cells, J. Biol. Chem. 1985, 260, 13844-13850.
23. Kim, H. K., Park, W. S., Kang, S. H., Warda, M. et al., Mitochondrial alterations in human gastric carcinoma cell line, Am. J. Cell. Physiol. 2007, 293, C761-771.
24. Modica-Napolitano, J. S., Aprille, J. R., Delocalized lipohilic cations selectively target the mitochondria of carcinoma cell, Adv. Drug Del. Rev. 2001, 49, 63-70.
25. Capuano, F., Guerrieri, F., Papa, S., Oxidative phosphorylation enzymes in normal and neoplastic cell growth, J. Bioenerg. Biomembr. 1997, 29, 379-384.
26. Capuano, F., Barone, M., D'Eri, N., Russo, E. et al., Urso-deoxycholate promotes protein phosphorylation in the cytosol of rat hepatocytes, Biochem. Mol. Biol. Int. 1997, 41, 329-337.
27. Cuezva, J. M., Ostronoff, L. K., Ricart, J., Lopez de Heredia, M. et al., Mitochondrial biogenesis in the liver during development and oncogenesis, J. Bioenerg. Biomembr. 1997, 29, 365-377.
28. Sun, A. S., Sepkowitz, K., Geller, S. A., A study of some mitochondrial and peroxisomal enzymes in human colonic adenocarcinoma, Lab. Invest. 1981, 44, 13-17.
29. Heerdt, B. G., Halsey, H. K., Lipkin, L. H., Augenlicht, L. H., Expression of mitochondrial cytochrome c oxidase in human colonic cell differentiation, transformation, and risk for colonic cancer, Cancer Res. 1990, 50, 1596-1600.
30. Luciakova, K., Kuzela, S., Increased steady-state levels of several mitochondrial and nuclear gene transcripts in rat hepatoma with a low content of mitochondria, Eur. J. Biochem, 1992, 205, 1187-1193.
31. Sul, H. S., Shrago, E., Goldfarb, S., Rose, F., Comparison of the adenine nucleotide translocase in hepatomas and rat liver mitochondria, Biochim. Biophys. Acta 1979, 551, 148-156.
32. Wallace, D. C., A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: A dawn for evolutionary medicine, Annu. Rev. Genet. 2005, 39, 359-407.
33. Brandon, M., Baldi, P., Wallace, D. C., Mitochondrial mutations in cancer, Oncogene 2006, 25, 4657-4662.
34. Riehm, H., Biedler, J. L., Cellular resistance to daunomycin in Chinese hamster cells in vitro, Cancer Res. 1973, 13, 409-412.
35. Juliano, R. L., Ling, V., A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants, Biochem. Biophys. Acta 1976, 455, 152-162.
36. Shen, D. W., Fojo, A., Robinson, I. B., Chin, R. et al., Multi-drug resistance of DNA-mediated transformants is linked to transfer of the human MDR1 gene, Mol. Cell. Biol. 1986, 6, 4039-4044.
37. Dano, K., Active outward transport of daunomycin in resistant ehrlich ascites tumor cells, Biochim. Biophys. Acta 1973, 323, 466-483.
38. Lampidis, T. J., Fourcade, A., Tapiero, H., Relationship of membrane potential to acquired and intrinsic multiple drug resistance, Jaquillat, C., Weil, M., Khayat, D. (Eds.), in: Neo-adjuvant Chemotherapy Inserm Colloquim, John Libbey Eurotext Ltd., London 1988, pp. 655-660.
39. Priebe, W., Perez-Soler, R., Design and tumor targeting of anthracyclines able to overcome multidrug resistance: A double-advantage approach, Pharmacol. Ther. 1993, 60, 215-234.
40. Pearce, H. L., Safa, A. R., Bach, N. J., Winter, M. A. et al, Essential features of the p-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multi-drug resistance, Proc. Natl. Acad. Set USA 1989, 86, 5128-5132.
41. Zamora, J. H., Pearce, H. L., Beck, W. T., Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemia cells, Mol. Pharmacol. 1988, 33, 454-462.
42. Ramu, A., Ramu, N., Gorodetsky, R., Reduced oubain-sensitive potassium entry as a possible mechanism of multidrug resistance in P388 cells, Biochem. Pharmacol. 1991, 42, 1699-1704.
43. Ramu, A., Ramu, N., Resistance to lipohilic cationic compounds in multidrug resistant leukemia cells, Leuk. Lymphoma 1993, 9, 247-53.
44. Zou, Y., Ling, Y. H., Van, N. T., Priebe, W., Perez-Soler, R., Antitumor activity of free and liposome-entrapped annamycin, a lipophilic anthracycline antibiotic with noneross-resistance properties, Cancer Res. 1994, 54, 1479-1484.
45. Priebe, W., Van, N. T., Perez-Soler, R., Removal of the basic center from doxorubicin partially overcomes multidrug resistance and decreases cardiotoxicity, Anticancer Drugs 1993, 4, 37-48.
46. Selassie, C. D., Hansch, C., Khwaja, T. A., Structure-activity relationships of antineoplastic agents in multidrug resistance, J. Med. Chem. 1990, 33, 1914-1919.
47. Edgar, R., Bibi, E., A single membrane-embedded negative charge is critical for recognizing positively charged drugs by the Escheria coli multidrug resistance protein MdfA, EMBO J. 1999, 18, 822-832.
48. Baguley, B. D., Ferguson, L. C., Relationship between the structure of analogs of amsacrine and their degree of cross-resistance to adriamycin-resistant P388 leukemia cells, Eur. J. Cancer Clin. Oncol. 1988, 24, 205-210.
49. Burke, T. G., Morin, M. J., Sartorelli, A. C., Lane, P. E., Tritton, T. R., Function of the anthracycline amino group in cellular transport and cytotoxicity, Mol. Pharmacol. 1987, 31, 552-556.
50. Lampidis, T. J., Kolonias, D., Podona, T., Israel, M. et al., Circumvention of P-GP MDR as a function of anthracycline lipophilicity and charge, Biochemistry 1997, 36, 2679-2685.
51. Dellinger, M., Pressman, B., Higgenson, C., Kolonias, D. et al., Structural requirements of simple organic cations for recognition by multi-drug resistant cells, Cancer Res. 1992, 52, 6385-6389.
52. Hait, W. N., Aftab, D. T., Rational design and preclinical pharmacology of drugs reversing multidrug resistance, Biochem. Pharmacol. 1992, 43, 103-107.
53. Pawagi, A. B., Wang, J., Silverman, M., Reithmeier, R. A. F., Deber, C. M., Transmembrane aromatic amino acid distribution in p-glycoprotein: A functional role in broad substrate specificity, J. Mol. Biol. 1994, 235, 554-564.
54. Burley, S. K., Petsko, G. A., Weakly polar interactions in proteins, Adv. Protein Chem. 1988, 39, 125-189.
55. Burley, S. K., Petsko, G. A., Aromatic-aromatic interaction: A mechanism of protein structure stabilization, Science 1985, 229, 23-28.
56. Tapiero, H., Nguyen-Ba, N., Lampidis, T. J., Relevance of cross-resistance to the chemical structure of different anthracyclines in multi-drug resistant cell, Pathol. Biol. 1994, 42, 328-337.
57. Brouty-Boye, D., Kolonia, D., Wu, C. J., Savaraj, N., Lampidis, T. J., Relationship of multidrug resistance to rhodamine-123 selectivity between carcinoma and epithelial cells: Taxol and vinblastine modulate drug efflux, Cancer Res. 1995, 55, 1633-1638.
58. Britten, C. D., Rowinsky, E. K., Baker, S. D., Weiss, G. R. et al., A phase I clinical and pharmokinetic study of the mitoconhdrial specific rhodamine dye analog MKT 077, Clin. Cancer Res. 2000, 6, 42-49.
59. Croop, J. M., Raymond, M., Haber, D., Devault, A. et al., The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues, Mol. Cell. Biol. 1989, 9, 1346-1350.
60. Fojo, A. T., Ueda, K., Slamon, D. J., Poplack, D. G., Gottesman, M. M., Pastan, I., Expression of a multidrug-resistance gene in human tumors and tissues, Proc. Natl. Acad. Sci. USA 1987, 84, 265-269.
61. Abou-Khalil, S., Abou-Khalil, W. H., Planas, L., Tapiero, H., Lampidis, T. J., Effects of rhodamine 123 on mitochondria isolated from sensitive and resistant friend leukemia cell variants, Biochem. Biophys. Res. Commun. 1985, 127, 1039-1044.
62. Modica-Napolitano, J. S., Weiss, M. J., Chen, L. B., Aprille, J. R., Rhodamine 123 inhibits bioenergetic function in isolated rat liver mitochondria, Biochem. Biophys. Res. Commun. 1984, 118, 717-723.
63. Mohanti, B. K., Rath, G. K., Anantha, N., Kannan, V. et al., Improving cancer radiotherapy with 2-deoxy-D-glucose: Phase I/II clinical trials on human cerebral gliomas, Int. J. Radial Oncol. Biol. Phys. 1996, 35, 103-111.
64. Vaupel, P., Kallinowski, F., Okunieff, P., Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: A review, Cancer Res. 1989, 49, 6449-6465.
65. Rofstad, E. K., Halsor, E. F., Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts, Cancer Res., 2000, 60, 4932-4938.
66. Liu, H., Hu, Y. P., Savaraj, N., Priebe, W., Lampidis, T. J., Hypoxia increases tumor cell sensitivity to glycolytic inhibitors: A strategy for solid tumor therapy [model C], Biochem. Pharmacol. 2002, 64, 1746-1751.
67. Liu, H., Hu, Y. P., Savaraj, N., Priebe, W., Lampidis, T. J., Hypersensitization of tumor cells to glycolytic inhibitors, Biochemistry 2001, 40, 5542-5547.
68. Maher, J. C., Krishan, A., Lampidis, T. J., Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy-D-glucose in tumor cells treated under hypoxic vs aerobic conditions, Cancer Chemother. Pharmacol. 2004, 53, 116-122.
69. Maher, J. C., Wangpaichitr, M., Savaraj, N., Kurtoglu, M., Lampidis, T. J., Hypoxic-induciblefactor-1 confers resistance to 2-deoxy-D-glucose in cells growing under hypoxia, Mol. Cancer Then 2007, 6, 732-741.
70. Maxwell, P. H., Pugh, C. W., Ratcliffe, P. J., Activation of the HIF pathway in cancer, Cum Opin. Genet. Dev. 2001, 11, 293-299.
71. Semenza, G. L., Roth, P. H., Fang, H., Wang, G. L., Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1, J. Biol. Chem. 1994, 269, 23757-23763.
72. Vaux, E. C., Metzen, E., Yeates, K. M., Ratcliffe, P. J., Regulation of hypoxia-inducible factor is preserved in the absence of a functioning mitochondrial respiratory chain, Blood 2001, 98, 296-302.
73. Wang, G. L., Semenza, G. L., General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia, Proc. Natl. Acad. Sci. USA 1993, 90, 4304-4308.
74. Zou, Y., Priebe, W., Stephens, L. C., Perez-Soler, P., Preclinical toxicity of liposome-incorporated annamycin: Selective bone marrow toxicity with lack of cardiotoxicity, Clin. Cancer Res. 1995, 1, 1369-1374.
75. Lampidis, T. J., Johnson, L. V., Israel, M., Effects of adriamycin on rat heart cells in culture: increased accumulation and nucleoli fragmentation in cardiac muscle v. nonmuscle cells, J. Mol. Cell. Cardiol. 1981, 13, 913-924.
76. Boutrid, H., Cebulla, C. M., Pina, Y., Jockovich, M. E. et al., Regional hypoxia in LHBetaTag murine retinoblastoma: Implication for novel treatments, Invest. Ophthalmol. Vis. Sci. 2008, 49, 2799-2805.
77. Raez, L. E., Langmuir, V., Tolba, K., Rocha-Lima, C. M. et al., Responses to the combination of the glycolytic inhibitor 2-deoxy-glucose [2-DG] and docetaxel [DC] in patients with lung and head and neck [H/N] carcinomas, J. Clin. Oncol. 2007, 25, 14025.